PDCD1 and small cell lung carcinoma: With the development of immunosuppression, PD‐1 and PD‐L1 inhibitors have demonstrated moderate but long‐lasting OS achievements in a subset of patients with SCLC when combined with platinum‐based chemotherapy [22].